Dr. Arnold currently serves as CSO at Biocept. In 2010 he founded AEGEA Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold also serves on the board of directors of Asuragen, as well as on the board of AEGEA. Previously, Dr. Arnold held various senior scientific and management positions at Molecular Biosystems (co-founder), Gen-Probe, Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder). Additionally, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. He is an inventor or co-inventor on 44 issued U.S. patents and more than 140 issued and pending patents worldwide. Dr. Arnold has authored more than 50 scientific publications. He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
CTCs and ctDNA as Sample Types: Identification, Enumeration, and Biomarker Analysis, Including High Sensitivity Mutation Analysis Using the CEE-Selector Assay
Tuesday, 28 October 2014 at 11:30
Add to Calendar ▼2014-10-28 11:30:002014-10-28 12:30:00Europe/LondonCTCs and ctDNA as Sample Types: Identification, Enumeration, and Biomarker Analysis, Including High Sensitivity Mutation Analysis Using the CEE-Selector AssaySELECTBIOenquiries@selectbiosciences.com
CTCs and ctDNA promise to be a compelling alternative as well as complementary with solid tumor tissue as a sample type. At Biocept, we are using a patented platform called Cell Enrichment and Extraction (CEETM) for the testing of CTCs. This platform is based on a micro-fluidic capture channel, and associated instrumentation that is manufactured by the Company. We can readily capture, enumeration, and interrogate CTCs for surface proteins using immunocytochemistry (ICC), conduct fluorescent in-situ hybridization (FISH) analysis, and at the same time, interrogate samples for mutations using a unique PCR method called CEE-SelectorTM. The CEE-SelectorTM, which has sensitivity of better than 1:10,000 (mutant:wild-type), is very effective for the analysis of genetic mutations associated with CTCs and ctDNA. Using these methodologies, a CTC assay has been commercially launched for breast cancer, OncoCEE-BR, and a series of other assays for lung, gastric, colorectal, melanoma, and prostate cancer will be introduced in the next two years using a combination CTCs and ctDNA as the sample types.
Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-10-28 11:30:002014-10-28 12:30:00Europe/LondonCTCs and ctDNA as Sample Types: Identification, Enumeration, and Biomarker Analysis, Including High Sensitivity Mutation Analysis Using the CEE-Selector AssaySELECTBIOenquiries@selectbiosciences.com
